Clinical trials
BCLC Stage B Hepatocellular Carcinoma clinical trials
Below are recruiting bclc stage b hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 119 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07436845Recruiting
Emotion and treatment for advanced liver cancer
This trial studies if emotional health affects how well targeted therapy and immunotherapy work for people with advanced liver cancer. You will receive chemotherapy directly into the liver along with targeted drugs and immunotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT07493044RecruitingPhase 1
Study of Super CAR-T for advanced liver cancer (GPC3-positive)
This trial tests a new cell therapy called Super CAR-T for people with advanced liver cancer that has GPC3 protein. It aims to see if the treatment is safe and effective. You may be eligible if your cancer has not responded to or stopped working on at least two standard treatments.
Guangzhou, GaungdongAges 18–75 - NCT05797805RecruitingPhase 1/Phase 2
Tegavivint for advanced liver cancer after prior treatments
This early-phase study tests tegavivint in people with advanced hepatocellular carcinoma (HCC), a type of liver cancer. It’s meant for cases where the cancer can’t be treated with curative surgery/local procedures or has progressed after standard systemic medicines.
Duarte, CaliforniaAges 18 years+ - NCT06323382Recruiting
Liver cancer: local therapy plus immunotherapy combo
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
Beijing, Beijing MunicipalityAges 18–80 - NCT06737913RecruitingPhase 2
Study of adebrelimab and bevacizumab with liver chemo for advanced liver cancer
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (bevacizumab) given through a vein or directly into the liver artery, along with standard chemotherapy directly into the liver artery, for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink or control the cancer.
Lanzhou, GansuAges 18 years+ - NCT05911633Recruiting
Doxorubicin beads for liver cancer that cannot be cut out
This trial tests BioPearl™ “microspheres” loaded with doxorubicin, delivered to the liver, for people with unresectable hepatocellular carcinoma (HCC). It may help shrink or control liver tumors when surgery or curative treatment isn’t possible.
BrusselsAges 18 years+ - NCT06485466RecruitingPhase 3
TACE plus Camrelizumab and Apatinib for liver cancer that can't be removed by surgery
This trial tests combining a liver-directed treatment (TACE) with two medications (Camrelizumab and Apatinib) to see if it works better for people with liver cancer that cannot be surgically removed. It is for people who have not had any previous treatment for their cancer.
Chengdu, SichuanAges 18–80 - NCT06461624RecruitingPhase 1
GPC3 CAR-T cell therapy for advanced liver cancer
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
Hangzhou, ZhejiangAges 18–70 - NCT07408804Recruiting
Lenvatinib alone vs. with chemoembolization for liver cancer
This trial compares the combination of two treatments—chemoembolization (TACE) and lenvatinib—against lenvatinib alone for people with liver cancer that cannot be removed by surgery. It aims to see if the combination works better.
DhakaAges 18–75 - NCT06109272RecruitingPhase 2/Phase 3
Livmoniplimab plus Budigalimab for liver cancer
This trial tests two investigational drugs, livmoniplimab and budigalimab, given together by IV for adults with advanced liver cancer (HCC) that cannot be removed by surgery or has spread. The study aims to see if this combination shrinks tumors and helps people live longer.
Duarte, CaliforniaAges 18 years+ - NCT06349980RecruitingPhase 2
Study of three drugs for liver cancer not yet treated
This trial is testing a combination of three drugs (HLX10, HLX04, and HLX53) to find the best dose and see if they help people with advanced liver cancer who have not had systemic treatment before. The goal is to shrink tumors and improve survival.
ShanghaiAges 18 years+ - NCT06530251RecruitingPhase 1/Phase 2
AK112 for advanced liver cancer (HCC)
This trial tests a new immunotherapy drug called AK112 for people with advanced liver cancer that hasn't spread to the brain or key blood vessels. It may be an option if you haven't had immunotherapy before and your liver is still working well.
Beijing, Beijing MunicipalityAges 18–75 - NCT06590246RecruitingPhase 1/Phase 2
Study of C-CAR031 for advanced GPC3-positive liver cancer
This trial tests a new type of cell therapy called C-CAR031, which is designed to target and attack liver cancer cells that have a protein called GPC3. It is for people with advanced liver cancer who have already tried other treatments and are looking for a new option.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07310173RecruitingPhase 2
Study of AST-3424 for advanced liver cancer with high AKR1C3
This trial tests a new drug called AST-3424 in people with advanced liver cancer that has gotten worse after prior treatment. It is for those whose tumor cells have high levels of a protein called AKR1C3, which the drug targets.
Nanjing, JiangsuAges 18–75 - NCT07351669Recruiting
Spectral CT to check TACE response in liver cancer
This study uses a special type of CT scan (spectral CT) to see how well liver cancer has responded to a previous TACE treatment. If you've already had TACE for your liver cancer, this scan may help your doctors decide on the next steps, such as surgery or another procedure.
NanjingAges 18–75 - NCT07088081Enrolling by invitation
Immunotherapy drugs for advanced liver cancer
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
Cairo, AbbasyaAges 18 years+ - NCT07064681Recruiting
AK104 plus TACE for resectable liver cancer
This trial tests whether adding an immunotherapy drug (AK104) to a standard liver cancer treatment (TACE) helps prevent the cancer from coming back after surgery. It is for people with early-stage liver cancer that can be surgically removed and who have a high risk of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT07039201Recruiting
A cell therapy for liver cancer that has progressed on other treatments
This study tests a new cell therapy (called CG-102-12C) for advanced liver cancer that has a specific marker (GPC3) and has stopped responding to standard treatments. The therapy uses your own immune cells, specially trained to attack the cancer. This might be an option if you have tried other treatments and they no longer work or cause bad side effects.
Hangzhou, ZhejiangAges 18–75 - NCT06427941RecruitingPhase 1
Study of BGB-B2033 drug for advanced solid tumors
This trial tests a new drug, BGB-B2033, alone or with other treatments, for people with advanced liver, stomach, lung, or germ cell cancers that have not responded to standard therapy. The goal is to see if the drug is safe and works against these tumors.
Goodyear, ArizonaAges 18 years+ - NCT07479485RecruitingPhase 1/Phase 2
MRG006A combo for advanced liver cancer
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05844046RecruitingPhase 2
Triple drug treatment for advanced liver cancer that can’t be removed
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
MunichAges 18 years+ - NCT06478927Recruiting
Palbociclib for advanced liver cancer after other treatments
This trial tests a drug called palbociclib for people with advanced liver cancer who have already tried at least two other treatments. The goal is to see if palbociclib can help shrink the cancer or slow its growth.
Zhengzhou, HenanAges 18–75 - NCT06915753RecruitingPhase 1
TYRA-430 for advanced liver cancer and other solid tumors
This trial tests an oral drug called TYRA-430 for people with advanced liver cancer (HCC) or other solid tumors that have changes in the FGF/FGFR pathway. It aims to see how safe the drug is and whether it can shrink tumors or slow cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07268131Recruiting
TITAN-HCC: Testing immunotherapy plus TACE for liver cancer beyond standard criteria
This trial tests a combination of an immunotherapy drug (QL1706) and a liver-directed procedure (TACE) before and after surgery for people with liver cancer that is larger or more advanced than the usual transplant criteria. The goal is to see if this approach can help shrink the tumor and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new BCLC Stage B Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bclc stage b hepatocellular carcinoma?
- Yes. Clin2 currently lists 119 recruiting bclc stage b hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bclc stage b hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bclc stage b hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- BCLC Stage C Hepatocellular Carcinoma
- Stage IV Hepatocellular Carcinoma AJCC v8
- Stage III Hepatocellular Carcinoma AJCC v8
- Stage IVA Hepatocellular Carcinoma AJCC v8
- Stage IVB Hepatocellular Carcinoma AJCC v8
- Stage IIIA Hepatocellular Carcinoma AJCC v8
- Stage IIIB Hepatocellular Carcinoma AJCC v8
- Hepatocellular Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.